a high density of macrophages. Apoptotic cell death increases the risk of plaque rupture by decreasing the number of viable smooth muscle cells necessary for collagen production and compromising the structural integrity of the fibrous cap following release of matrix metalloproteinases from dead macrophages. 8 Furthermore, plaque thrombogenicity is enhanced because lesion-resident cells undergoing apoptosis express active cell surface tissue factor (TF), 9 the major physiological initiator of the coagulation cascade. 10 Previous studies have demonstrated that the absence of specific proapoptotic factors such as Bax 11 or Rb 12 decreases macrophage apoptosis as well as necrotic core size in hyperlipidemic mice. Consistent with these findings, a reduction in apoptosis and plaque necrosis was observed in advanced atherosclerotic lesions from ApoE À/À mice deficient in the ER stress effector CHOP.
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TDAG51 is a member of the pleckstrin homology-like domain family having proapoptotic characteristics. 13 Furthermore, TDAG51 is induced by ER stress, [14] [15] [16] and its overexpression in human vascular endothelial cells induces apoptotic cell death by disrupting cytoskeletal structure and impairing cell adhesion. 15 Conversely, deficiency of TDAG51 contributes to apoptosis resistance and growth dysregulation in metastatic melanomas in vivo. 17 TDAG51 can also regulate energy metabolism by modulating adipogenesis and hepatic lipogenesis, which correlates with mature-onset metabolic disease. 18 Several lines of evidence implicate TDAG51 in atherosclerotic lesion development. TDAG51 expression is increased in lesionresident macrophages and endothelial cells during all stages of atherogenesis. 6, 15 Furthermore, TDAG51 mRNA is significantly increased in cultured human vascular endothelial cells following exposure to athero-prone waveform stimulation. 19 Although these findings suggest that TDAG51 contributes to the atherosclerotic process, it is currently unknown if TDAG51 is causally related to atherogenesis or if its mechanism of action stems from its previously described role as a proapoptotic factor. In this report, we investigated whether loss of TDAG51 alters the development and progression of atherosclerosis by crossing TDAG51
À/À mice 20 with ApoE À/À mice, an established hyperlipidemic mouse model of accelerated atherosclerosis. 21 Our findings provide the first in vivo evidence that deficiency of TDAG51 reduces atherosclerotic lesion growth. Furthermore, such inhibition of atherogenesis because of TDAG51 deficiency likely involves the action of PPARc on specific cellular targets and pathways that are known to affect atherosclerotic lesion development and progression.
Methods

Mice and Dietary Conditions
ApoE À/À mice were obtained from the Jackson Laboratory (Bar Harbor, ME). TDAG51-deficient (TDAG51 À/À ) mice have been previously described. 20 TDAG51 À/À (knockout [KO]) mice were backcrossed >9 generations onto a C57BL/6 background. TDAG51-deficient mice were crossbred with TDAG51 +/+ /ApoE À/À mice (also on a C57BL/6 background) to generate TDAG51 À/À /ApoE À/À double-knockout (dKO) mice as well as ApoE À/À littermate controls. Given previous studies showing that the PPARc ligand effect on atherosclerosis is sex specific toward male mice, 22 only male mice were used in this study. Mice were housed with free access to regular chow diet. All experimental procedures using mice were approved by the McMaster University Animal Research Ethics Board.
Mouse Genotyping Using Polymerase Chain Reaction Isolation of Peritoneal Macrophages
Wild-type C57BL/6 and TDAG51 À/À mice were injected intraperitoneally with 500 lL of 80 lg/mL concanavalin A. 7 Peritoneal macrophages were harvested 3 days postinjection.
Macrophages were cultured in RPMI-1640 containing 10% FBS and 50 ng/mL macrophage colony stimulating factor.
Isolation and Culture of Mouse Lung Microvascular Endothelial Cells
Mouse lung microvascular endothelial cells (MLECs) were isolated and cultured using a protocol derived from previous studies 24 and Miltenyi Biotec (Auburn, CA). Briefly, mouse lung cells were incubated with MACS LSEC (CD146) microbeads (130-092-007, Miltenyi Biotec) and subsequently eluted from a MACS Separation LS column (130-042-401, Miltenyi Biotec). MLECs were cultured in endothelial cell growth medium (CC-3121; Lonza, Walkersville, MD).
Measurement of Total Cholesterol, Triglyceride, and Glucose
Plasma total cholesterol was measured using an Infinity cholesterol measurement kit (Thermo Electron Corporation, Melbourne, Australia). Triglyceride and glucose levels in mice plasma were determined similarly to the above described cholesterol assay (Thermo Electron Corporation). Macrophages were pretreated in the presence or absence of 10 lmol/L GW9662 in FBS-deficient media for 4 hour before incubation with acetyl-LDL (50 lg/mL) or acetyl-LDL+GW9662 (10 lmol/L) for 24 to 48 hours. Cellular lipids were isolated via Bligh and Dyer chloroform:methanol extraction 25 with subsequent assessment of total and free cholesterol levels using Cholesterol E and Free Cholesterol E kits (Wako Pure Chemical Industries, Ltd, Osaka, Japan). Lipid content was normalized against cellular protein and the data expressed as fold-change.
Measurement of Cholesterol Efflux in Peritoneal Macrophages
HDL/APOA1-dependent cholesterol efflux to the medium was determined as described previously. 26 
Lactate Dehydrogenase Release Assay
Peritoneal macrophages and MLECs were incubated in the presence or absence of 2.5 lg/mL tunicamycin, 100 nmol/L thapsigargin, or 10 lmol/L 7-ketocholesterol (7-KC) for 24 hours. Lactate dehydrogenase release was measured using a Cytotoxicity Detection Kit (Roche, Laval, Canada).
Detection of Superoxide
Superoxide levels in cells were measured using fluorescentdye dihydroethidium (Invitrogen, Carlsbad, CA) as previously described. 16 Fluorescence intensity is reported as relative fluorescence units (RFU).
Measurement of Mouse Plasma Lipid Profiles Using FPLC
Mouse plasma was fractionated into lipid components using gel filtration-fast protein liquid chromatography (FPLC), as described previously. 27 
Tissue Sample Preparation
Following perfusion-fixation with 10% neutral buffered formalin, 6, 28 hearts (including the aortic roots) were cut transversely and embedded in paraffin. Serial sections, 4 lm thick, were cut starting from the aortic root origin and collected for measurement of lesion size (hematoxylin/eosin staining) and immunohistochemical analyses. 29 In each mouse, the atherosclerotic lesion area was measured in 5 sections separated by 80 lm (ie, within 320 lm from the aortic valve). 29 The lesion was traced manually and measured using computer-assisted image analysis equipment (Olympus BX41 microscope, Olympus DP70 CCD camera, and ImagePro Plus software). Lesion size is expressed as the mean of 5 sections. Therefore, this number is directly proportional to the volume of the lesions in the first 320 lm of the ascending aorta.
Immunohistochemical Analysis
Immunohistochemical staining of atherosclerotic lesions was performed as described previously. 6, 29 Sections were counterstained with hematoxylin. Human carotid arteries were obtained at the time of endarterectomy from consenting patients. The protocol was approved by the institutional ethics review boards of Hamilton Health Sciences and St. Joseph's Healthcare. Tissue was fixed with formalin and embedded in paraffin. Double immunofluorescence was performed on the sections as described previously. 29 Antibodies used for immunostaining were anti-GRP78 (sc-1050; Santa Cruz, CA), anti-cleaved caspase-3 (9661; Cell Signaling, Danvers, MA), anti-Mac-3 (55322; BD Pharmingen, San Diego, CA), anti-KDEL (SPA-827; Enzo Life Sciences, Farmingdale, NY), anti-PDI (SPA-891; Enzo Life Sciences), antiPPARc (07-466; Upstate, Billerica, MA), anti-Prdx-1 (SA-356; Enzo Life Sciences), anti-SMA (A2547; Sigma, St. Louis, MO), and anti-CD3 (A0452; DAKO, Glostrup, Denmark). Nonspecific immunostaining was not detected in control sections. Controls consisted of nonimmune IgG as the primary antibody or the secondary antibody alone. A TACS 2TdT In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg, MD) was used for TUNEL staining. Collagen was stained with Masson's trichrome (HT-15-1KT; Sigma).
Immunostaining was quantified by extracting the blue component of the RGB image, thresholding for the staining, and measuring the stained area as well as the total area of the lesion (by manual tracing) using ImagePro 6.3 software. Results are expressed as a percentage of the total lesion area. The association between SNPs and myocardial infarction was performed by logistic regression analysis that adjusted for age and sex. A combined analysis of the results from the UCSF study and the WTCCC study was carried out using the fixed-effects Mantel-Haenszel method that combined odds ratios across these studies; homogeneity of the odds ratios was assessed by the Breslow-Day test.
Identification of Insulin and Glucagon in b Cells
Results
Loss of TDAG51 Reduces Atherosclerotic Lesion Development and Progression
To investigate the role of TDAG51 in atherosclerotic lesion development, we generated TDAG51
littermate/sex controls ( Figure 1 ). To focus on the effect of TDAG51 deficiency, male mice were maintained on a control chow diet, as opposed to a high-fat chow diet, to minimize the potential contribution of obesity and insulin resistance 32 to atherosclerotic lesion development and necrosis. Total plasma lipids, glucose, and inflammatory cytokines, as well as aortic atherosclerotic lesion size and composition, were analyzed at 25 and 40 weeks of age. No significant differences in total plasma cholesterol or triglycerides were observed between dKO and ApoE À/À mice (Figure 2A and 2B). Consistent with these findings, plasma lipid profiles were indistinguishable between these groups at 25 weeks of age ( Figure 2C ). No significant changes in body weight (data not shown), plasma glucose level ( Figure 2D ), or morphology of pancreatic b cells from the islets of Langerhans ( Figure 3 ) were observed in dKO and ApoE À/À mice.
As reported previously, 6, 15 À/À /ApoE À/À mice. Mouse genomic DNA was amplified by PCR using specific primer sets, and the PCR products were separated on agarose gels to identify mice containing the wild-type TDAG51 allele (wt-TDAG51) (A) or the disrupted TDAG51 allele (ko-TDAG51) (B). PCR amplification and gel electrophoresis was also used to identify mice that were deleted for the ApoE allele (C). Neg, negative controls for PCR reactions (A through C). Liver tissue obtained from PCR identified TDAG51
mice was homogenized, and total protein lysates were examined by immunoblotting using an anti-TDAG51 antibody (D). b-actin was used as a loading control. TDAG51 indicates T-cell death-associated gene 51; PCR, polymerase chain reaction; ApoE, apolipoprotein E; ko, knockout; dKO, double knockout. muscle cells, in the atherosclerotic cap region ( Figure 6 ). However, at 25 and 40 weeks of age, there were no significant differences in the content of either macrophages or smooth muscle cells in the lesions of dKO and ApoE À/À mice ( Figure 6 and Table 1 ). In support of the en face lipid staining ( Figure 5C ) and increased necrotic core size ( Figure 5D and 5E), cholesterol crystals were prevalent in the necrotic core regions of the 25-week-old ApoE À/À mice ( Figure 5D ). Collagen content in the lesions, as measured by Masson's trichrome staining, showed high intralesion variability and did not differ significantly between the ApoE À/À and dKO groups (23.4% versus 27.9%, P=0.48; Figure 7 ). However, at 40 weeks dKO mice exhibited less vascular calcification, as assessed by von Kossa staining, compared with ApoE À/À mice ( Figure 8 ). Inflammatory cytokines are known to influence several cellular processes that accelerate atherosclerotic lesion growth and stability. 33 However, loss of TDAG51 had no significant effect on plasma levels of proinflammatory cytokines, including IL-12, TNF-a, or MCP-1, up to 40 weeks (Table 2 ). These data suggest the decrease Figure 9A ). In support of these findings, we observed that TDAG51 À/À peritoneal macrophages ( Figure 9B ) were resistant to cell death induced by ER stress and oxidative stress.
TDAG51 Negatively Regulates the Expression of PPARc and Its Downstream Targets
To provide further mechanistic insight into the antiatherogenic effects of TDAG51 deficiency, we investigated the expression of PPARc because of its involvement in modulating various pathways contributing to atherogenesis, such as inflammation, lipid metabolism, and oxidative stress. Furthermore, we have previously observed an inverse correlation between TDAG51 and PPARc expression in 3T3-L1 cells. 18 Prior studies have demonstrated the expression of PPARc in lesion-resident macrophages from LDLR À/À mice. 36 To determine whether deficiency of TDAG51 alters the expression of PPARc in lesional macrophages, paraffin sections from the aortic roots of chow-fed dKO and ApoE À/À mice after 15 or 25 weeks were immunostained for PPARc ( Figure 10A ). Intense nuclear staining for PPARc was observed in lesionresident macrophages from dKO mice compared with ApoE À/À mice. As a positive control, nuclear staining for PPARc was observed in adipocytes from dKO and ApoE À/À mice ( Figure 10B ). Again, the intensity of nuclear staining for PPARc was increased in adipocytes from dKO mice as well as in cultured TDAG51 À/À macrophages ( Figure 10C ). Furthermore, TDAG51
À/À peritoneal macrophages exhibited increased mRNA expression of PPARc (2.8AE0.5-fold, P<0.05) and its target gene, LXRa (1.9AE0.3-fold, P<0.05), as well as PPARc-inducible gene ABCG1 (1.7AE0.1-fold, P<0.05), but not ABCA1, compared with wild-type macrophages ( Figure 11 ).
Consistent with these findings, reintroduction of TDAG51 using a retrovirus expression construct caused a significant reduction in PPARc mRNA expression (P<0.001) in TDAG51 À/À mouse embryonic fibroblasts (data not shown). Furthermore, siRNA knockdown of TDAG51 in HeLa cells also showed enhanced PPARc expression (data not shown).
TDAG51 Deficiency Enhances PPARc-Dependent Inhibition of Inflammatory Cytokine Expression in Macrophages
Inflammation has been shown to modulate several processes that contribute to atherogenesis and lesion stability. macrophages, but not THP-1 monocytes, as well as aortic endothelial cells (HAECs) and aortic smooth muscle cells (HASMCs), expressed TDAG51 protein ( Figure 12C ). Consistent with these findings, TDAG51 was also expressed in macrophages (CD68), smooth muscle cells (SMA), and endothelial cells (vWF) in lesions from human carotid arteries, as determined by dual immunohistochemistry ( Figure 12D ).
Loss of TDAG51 Increases Cholesterol Efflux in Cultured Peritoneal Macrophages
Given that PPARc increases reverse cholesterol transport in lesion-resident macrophages and is considered atheroprotective, 37, 38 we examined the effects of TDAG51 deficiency on macrophage foam cell formation and cholesterol efflux. To assess macrophage foam cell formation, peritoneal macrophages were cultured in the absence or presence of acetylated low-density lipoprotein (LDL), and the accumulation of intracellular lipids was examined by ORO staining ( Figure 13A ). TDAG51 À/À macrophages showed a significant reduction in ORO staining at 48 hours compared with wildtype macrophages ( Figure 13B ). TDAG51 À/À macrophages also accumulated significantly less cellular total cholesterol (1.8AE0.1-fold versus 3.1AE0.1-fold, P<0.05; Figure 13C ) and free cholesterol (0.9AE0.1-fold versus 1.5AE0.1-fold, P<0.05; Figure 13D ) after incubation with acetyl-LDL (50 lg/mL) for 48 hours, relative to wild-type macrophages. Consistent with the hypothesis that increased PPARc results in reduced lipid accumulation, the PPARc antagonist GW9662 (10 lmol/L) increased cellular total cholesterol in both wild-type and KO macrophages after 48 hours incubation with 50 lg/mL acetyl-LDL, compared with acetyl-LDL treatment alone (Figure 13E ). To determine whether the reduced lipid accumulation with TDAG51 deficiency was the result of increased cholesterol efflux, macrophages were loaded with agonists induce the expression of ABCG1, a protein transporter mediating cholesterol efflux from macrophages. 39 Consistent with these results, ABCG1 mRNA expression, but not ABCA1 expression, was significantly increased in TDAG51 À/À peritoneal macrophages compared with wild-type macrophages ( Figure 11 ). Taken together, these results suggest the cumulative effect of increased cholesterol efflux over time leads to significantly lower intracellular total and free cholesterol levels in TDAG51 À/À macrophages.
Effect of TDAG51 Deficiency on Peroxiredoxin 1 Expression
Recent studies have suggested that loss of peroxiredoxin 1 (Prdx-1), a member of a ubiquitous family of antioxidant enzymes, 40 reduces endothelial cell activation and early atherosclerosis. 41 Because an increase in Prdx-1 expression could contribute to the observed cytoprotective effect of TDAG51 deficiency against oxidative stress ( Figure 9B ), lesions from dKO and ApoE À/À mice were immunostained for Prdx-1.
At both 25 (36.4% versus 8.4%, P=0.10) and 40 (31.3% versus 11.2%, P=0.15) weeks, the percentage of Prdx-1 immunopositivity in the endothelium was increased in dKO mice compared with ApoE À/À controls ( Figure 14A and 14B).
Furthermore, when mice from 25 and 40 weeks were combined, dKO mice exhibited significantly more Prdx-1 immunopositivity than ApoE À/À mice (33.2% versus 10.1%, P=0.015; Figure 14C ). In addition, TDAG51 À/À peritoneal macrophages ( Figure 14D ) as well as lung microvascular endothelial cells ( Figure 15A ) exhibited increased Prdx-1 Figure 14F ). Rosiglitazone treatment also induced Prdx-1 protein expression in microvascular endothelial cells, although no significant differences were observed between TDAG51 À/À and wild-type cells ( Figure 15A ). Although TDAG51 À/À mouse aortic smooth muscle cells also exhibited increased resistance to oxidative stress-induced cell death in vitro (Figure 16 ), no differences in lesion smooth muscle cell apoptosis were observed in vivo ( Figure 9A ).
Single-Nucleotide Polymorphisms in the Human TDAG51 Gene Are Associated With CVD
The WTCCC case-control study of CVD published data for 5 single-nucleotide polymorphisms (SNPs) in the 56-kbp region that included the TDAG51 gene. 30 Two of these SNPs (rs10880022 and rs2367446) were associated with CVD in this study (Table 3) ; both remained significant after Bonferroni correction for testing 5 SNPs. We genotyped rs10880022 and rs2367446 in the UCSF study 31 and found that rs2367446
was also associated with myocardial infarction (OR, 1.24; 95% CI, 1.04 to 1.48; P=0.019). A combined analysis of rs2367446 in both studies found that it was associated with CVD, with an odds ratio of 1.15 (95% CI, 1.07 to 1.24, P=0.00031; Table 4 ); this P value remained significant after Bonferroni correction for testing 5 SNPs.
Discussion
Several lines of evidence suggest that TDAG51 modulates lesion progression and plaque stability. First, TDAG51 is expressed in athero-prone vascular endothelial cells 19 as well as lesion-resident macrophages and endothelial cells from ApoE À/À mice with diet-induced hyperhomocysteinemia. 6, 15 Second, TDAG51 is expressed in apoptotic cells within the A, Representative images of atherosclerotic lesions from 5 mice per group were stained for TUNEL and cleaved caspase-3. Microscope magnification 920. B, Peritoneal macrophages isolated from wildtype C57BL/6 (C57) mice or TDAG51 À/À mice were treated with 2.5 lg/mL tunicamycin (Tm), 100 nmol/L thapsigargin (Tg), or 10 lmol/L 7-ketocholesterol (7-KC) for 24 hours. Cytotoxicity was determined by measuring LDH release. MeanAESE from 5 independent experiments are shown. *P<0.05 relative to C57 controls. C, Negative controls for IHC sections. Primary antibodies were omitted, and only secondary antibodies were used (anti-mouse, antirat, or anti-rabbit, with heat-induced epitope retrieval [HIER] where specified). Negative control for the TUNEL staining had no terminal deoxynucleotidyl transferase (TdT) added to the staining mixture. TDAG51 indicates T-cell death-associated gene 51; ApoE, apolipoprotein E; dKO, double knockout; LDH, lactate dehydrogenase; IHC, immunohistochemistry; PPARc, peroxisome proliferator-activated receptor c; ab, antibody; NT, nontreated.
lipid-rich necrotic core. 6, 15 Third, overexpression of TDAG51 in cultured human vascular endothelial cells leads to detachment-induced apoptosis. 15, 34 Additional observations of increased TDAG51 expression during all stages of atherogenesis in the absence of HHcy 6 suggest that other pathophysiological conditions that induce ER stress and/or TDAG51 expression modulate lesion growth and stability. In support of this hypothesis, we have reported that peroxynitrite, a proatherogenic agent generated from nitric oxide and superoxide, induces ER stress, TDAG51 expression, and apoptosis in cultured vascular endothelial cells. 16 Given that ER stress plays a major role in lesion progression and plaque stability [5] [6] [7] 42, 43 and that TDAG51 is an ER stress-inducible gene 6,14-16 expressed in lesion resident macrophages and endothelial cells, we sought to investigate the causal role of TDAG51 in atherogenesis. In this study, TDAG51 À/À /ApoE À/À dKO male mice showed significant reductions in lesion and necrotic lipid core sizes in aortic roots at 25 and 40 weeks compared with age-matched ApoE À/À controls. Thus, in the setting of a normal chow diet, ApoE À/À mice lacking TDAG51 exhibited reduced growth of atherosclerotic lesions. As TDAG51 is expressed in lesion-resident cells undergoing apoptotic cell death, 6 ,15 a potential mechanism through which TDAG51 deficiency contributes to the reduced atherosclerotic lesion size and necrosis observed in this study is decreased lesional apoptosis. Decreased lesional necrosis from dKO mice was associated with reduced apoptosis, as determined by immunohistochemical staining for TUNEL and cleaved caspase-3. Our data are consistent with the hypothesis that retardation of the rate of necrotic core and lesion growth is in À/À and C57BL/6 (C57) peritoneal macrophages at the plane of the nuclei (arrows). In C57 macrophages, little PPARc (green) was visualized within the nucleus, whereas in TDAG51 À/À macrophages, PPARc (green) was found to colocalize (merged green and red producing yellow) with nucleic acids (red) as shown by ethidium bromide (EtBr) staining in the nuclei (arrows). Representative images from 3 independent experiments are shown. Scale bar=10 lm. TDAG51 indicates T-cell death-associated gene 51; ApoE, apolipoprotein E; dKO, double knockout; PPARc, peroxisome proliferator-activated receptor c. part a consequence of increased resistance to macrophage cell death resulting from TDAG51 deficiency. Consistent with this hypothesis, peritoneal macrophages isolated from TDAG51 À/À mice were resistant to ER and oxidative stress-induced cell death. Cytoprotection was associated with increased levels of Prdx-1 in lesions of dKO mice as well as in TDAG51
À/À macrophages and endothelial cells. This was accompanied by reduced superoxide levels in TDAG51 À/À macrophages at both baseline and when exposed to oxidative stress, a finding consistent with previous studies. 44, 45 These data suggest that the elevation of Prdx-1 levels associated with TDAG51 deficiency contributes to increased resistance to oxidative stress-induced apoptosis, thereby reducing atherosclerotic lesion progression and rupture. This is consistent with the finding that Prdx-1 deficiency in ApoE À/À mice causes endothelial activation (increased leukocyte rolling, endothelial P-selectin, and vWF expression) and accelerates atherosclerosis. 41 Further studies should clarify whether TDAG51-mediated endothelial dysfunction contributes to atherogenesis. It has been previously reported that inhibiting macrophage apoptosis increases atherosclerotic lesion size. Macrophagespecific deletion of the proapoptotic gene p53 resulted in significantly increased lesion area after 15 or 20 weeks on a high-fat diet in LDLR À/À mice. 46 However, the authors attributed the larger lesion size to increased cell proliferation rather than decreased apoptosis, as no significant differences in apoptosis were observed. Liu et al 11 demonstrated that macrophage-specific deletion of Bax, a proapoptotic protein, decreased macrophage apoptosis and was associated with increased lesion area in LDLR À/À mice after 10 weeks on a Western diet. Alternatively, deletion of the macrophage apoptosis inhibitory factor (AIM) was associated with increased apoptosis and smaller lesion area in LDLR À/À mice after 5 or 12 weeks on a Western diet. 47 Given the variability in genetic mouse models, diets used, and stage of atherosclerosis examined, a direct comparison to the current study is not possible. However, in the current study, in which lesions were assessed in dKO mice on a chow diet at later times (25 and 40 weeks) than the above studies (5 to 20 weeks on high-fat or Western diets), data are consistent with the hypothesis that elevated macrophage apoptosis leads to reduced atherosclerosis at early stages and increased atherosclerosis at later stages of lesion growth. Furthermore, given that the model used in our study was global ablation of the TDAG51 gene, the observed reduction in lesion size may not be solely attributable to decreased macrophage apoptosis; other cell types and mechanisms may be involved. Previous studies have indicated that PPARc acts as a positive regulator of antioxidant defenses. 48 Consistent with the inverse correlation between TDAG51 deficiency and PPARc expression, rosiglitazone treatment induced Prdx-1 protein expression by 23% (P<0.05) in TDAG51 À/À macrophages, compared with 12% (P<0.05) in wild-type macrophages ( Figure 14F ). These findings are consistent with previous studies showing that 15d-PGJ 2 , a natural PPARc agonist, induces expression of antioxidant proteins including Prdx-1 49 and supports the hypothesis that the increased Prdx-1 expression associated with TDAG51 deficiency is a consequence of elevated expression and/or activity of PPARc, leading to the reduced atherosclerotic lesion growth observed in the dKO mice. Given the ability of TDAG51 to modulate transcriptional activity, 13 we are currently investigating the possibility that TDAG51 modulates PPARc transcriptional activity and/or nuclear localization. It is well established that PPARc activates reverse cholesterol transport in lesion-resident macrophages. À/À /ApoE À/À (dKO) or ApoE À/À mice were placed on control chow diet. Atherosclerotic lesions from aortic roots of (A) 25-week-old mice or (B) 40-week-old mice were sectioned and consecutive sections immunostained for Prdx-1 and von Willebrand factor (vWF). Arrows indicate endothelium; arrowheads indicate macrophages/foam cells. Scale bar=100 lm. Representative images are shown from 5 mice per group. C, Percentage of Prdx-1 positivity in endothelium (measured as the length of Prdx1-positive endothelium divided by the total length of endothelium as immunostained with vWF) of 25-and 40-week-old dKO and ApoE À/À mice. The averages of 5 sections per mouse were assessed. *P<0.05 compared with ApoE À/À (n=8 to 9 for each genotype). D, Peritoneal macrophages isolated from TDAG51 À/À mice exhibited elevated levels of Prdx-1 protein, as determined by immunoblotting. Data are shown as meanAESE (n=9). *P<0.05 relative to C57BL/6 (C57) macrophages. E, TDAG51 À/À peritoneal macrophages displayed lower levels of superoxide at both baseline and when subjected to 10 lmol/L 7-ketocholesterol (7-KC). MeanAESE from 6 independent experiments is shown. *P<0.05 relative to C57 macrophages. F, Peritoneal macrophages from C57BL/6 or TDAG51 À/À mice were incubated in the presence or absence of 20 lmol/L rosiglitazone (Rosi) for 18 hours and then immunoblotted for Prdx-1. Data are shown as meanAESE (n=9). *P<0.05 vs C57 controls;^P<0.05 vs respective nontreated (NT) macrophages. TDAG51 indicates T-cell deathassociated gene 51; Prdx-1, peroxiredoxin-1; ApoE, apolipoprotein E; dKO, double knockout; RFU, relative fluorescence unit.
Furthermore, PPARc ligands promote the reduction of atherosclerotic lesions, 50, 51 whereas the conditional knockout of macrophage PPARc enhances atherosclerosis without altering plasma lipid levels. 52 We observed increased cholesterol efflux as well as increased expression of ABCG1 in TDAG51 À/À peritoneal macrophages. TDAG51 À/À macrophages, compared with wild-type cells, also accumulated fewer lipids, suggesting a reduction in foam cell formation.
We recently reported that TDAG51 deficiency induced ageassociated adipogenesis and hepatic steatosis in TDAG51 À/À mice, 18 further implicating PPARc in modulating the effects of TDAG51 deficiency. Taken together, our results suggest that TDAG51 deficiency, despite its effects on adipogenesis and hepatic lipogenesis, reduces atherosclerotic lesion growth via activation of multiple cellular pathways that regulate apoptosis, antioxidant status, and lipid storage/export. Although studies reporting the beneficial role of PPARc agonists in mitigating atherogenesis have been fairly consistent in mouse models, some controversy exists over the cardiovascular risk associated with the use of thiazolidinediones (TZDs) in patients. Several reports have indicated rosiglitazone is associated with significantly increased risk of myocardial infarction. 53, 54 In contrast, others have found the evidence for an association between rosiglitazone and myocardial infarction and CVD mortality to be inconclusive. 55 Furthermore, pioglitazone, another PPARc agonist, was reported to have significantly reduced cardiovascular risk in the PROactive study in diabetic patients with preexisting CVD. 56 Given the current debate over the potential beneficial and adverse events associated with TZDs in regard to CVD risk, it remains to be determined whether increased PPARc associated with TDAG51 deficiency and decreased atherosclerotic lesion growth in a mouse model can be extrapolated to a clinical setting. It should also be noted that this mechanism is likely not the only one that drives the antiatherogenic effect of TDAG51 deficiency. This could reflect TDAG51's role in apoptosis or signaling pathways that modulate macrophage viability and lipid metabolism.
The genetic association results from 2 independent casecontrol studies 30, 31 suggest that genetic variants in the TDAG51 region are associated with CVD. This finding is intriguing given the biological evidence for this gene in atherosclerosis. However, meta-analyses of genomewide association studies 57, 58 did not find an association between SNPs in the TDAG51 region and CVD at the genomewide significance level (P<5910 À8 ). Therefore, the genetic association results we report here may have overestimated the risk associated with the SNPs we examined. Additional studies are thus required to further evaluate whether genetic variations in the TDAG51 gene are associated with altered expression of this gene and CVD. Functional characterization of these SNPs will also be helpful to understand the potential role of these SNPs in CVD. Because rs2367446 is in an intergenic region 20 kbp from TDAG51, it is possible that this SNP affects transcription of the TDAG51 gene. In summary, we have characterized a previously unknown role for TDAG51 in modulating atherosclerotic lesion development and progression while addressing the underlying cellular mechanisms by which TDAG51 deficiency modulates these processes. Because the effects of TDAG51 are mediated by multiple pathways that affect lesion development and stability, our findings provide a unique opportunity to develop novel therapeutic approaches that decrease the risk of CVD by targeting TDAG51 expression and/or activity.
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